The Kaplan–Meier overall survival (OS) analysis from GEPIA2 database depicted that pancreatic cancer patients with high CASC19 expression exhibited significantly poorer survival than the PDAC patients with low expression of CASC19 (Fig. 1G). The gene discussed is CASC19; the disease is familial pancreatic carcinoma.